These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 187150)

  • 21. Antibody to herpes simplex virus (HSV) ICP-35 proteins after HSV challenge of animals immunized with HSV subunit vaccines.
    Bernstein DI; Stanberry LR; Kappes JC; Burke RL; Myers MG
    J Infect Dis; 1988 Jun; 157(6):1178-86. PubMed ID: 2836519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune responses to DNA free herpes simplex proteins in man.
    Cappel R; Sprecher S; de Cuyper F
    Dev Biol Stand; 1982; 52():345-50. PubMed ID: 6299843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Native HSV glycoprotein D subunit vaccine: analysis of in vitro T-cell activation and antigen presentation.
    Ishizaka ST; Mishkin EM
    Viral Immunol; 1991; 4(3):187-93. PubMed ID: 1667262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preinfection prophylaxis with herpes simplex virus glycoprotein immunogens: factors influencing efficacy.
    Stanberry LR; Myers MG; Stephanopoulos DE; Burke RL
    J Gen Virol; 1989 Dec; 70 ( Pt 12)():3177-85. PubMed ID: 2558156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunomodulation of experimental murine herpes simplex keratitis: I. UV-HSV protection.
    Thompson P; Wells PA; Sandstrom IK; Opremcak EM; Millin JA; Daigle JA; Foster CS
    Curr Eye Res; 1988 Nov; 7(11):1043-9. PubMed ID: 2854036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Indices of lymphocyte functional activity in patients with recurrent cutaneous-genital herpes during treatment with a herpes vaccine].
    Karpovich LG; Blokha VV; Kalashnikova TV; Bychkova AA; Semenova TB
    Vopr Virusol; 1986; 31(2):200-5. PubMed ID: 3014750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune response to a DNA free herpes simplex vaccine in man.
    Cappel R; Sprecher S; Rickaert F; de Cuyper F
    Arch Virol; 1982; 73(1):61-7. PubMed ID: 6289778
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Native herpes simplex virus glycoprotein D vaccine: immunogenicity and protection in animal models.
    Mishkin EM; Fahey JR; Kino Y; Klein RJ; Abramovitz AS; Mento SJ
    Vaccine; 1991 Mar; 9(3):147-53. PubMed ID: 1645898
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant interleukin 2 as an adjuvant for vaccine-induced protection. Immunization of guinea pigs with herpes simplex virus subunit vaccines.
    Weinberg A; Merigan TC
    J Immunol; 1988 Jan; 140(1):294-9. PubMed ID: 2826591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulation of expression of herpes simplex virus (HSV) glycoprotein D in vaccinia recombinants affects their ability to protect from cutaneous HSV-2 disease.
    Wachsman M; Aurelian L; Smith CC; Perkus ME; Paoletti E
    J Infect Dis; 1989 Apr; 159(4):625-34. PubMed ID: 2538519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens.
    Karem KL; Bowen J; Kuklin N; Rouse BT
    J Gen Virol; 1997 Feb; 78 ( Pt 2)():427-34. PubMed ID: 9018066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of DNA priming-protein boosting on enhancing humoral immunity and protecting mice against lethal HSV infections.
    Soleimanjahi H; Roostaee MH; Rasaee MJ; Mahboudi F; Kazemnejad A; Bamdad T; Zandi K
    FEMS Immunol Med Microbiol; 2006 Feb; 46(1):100-6. PubMed ID: 16420602
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Postexposure vaccination with a virion host shutoff defective mutant reduces UV-B radiation-induced ocular herpes simplex virus shedding in mice.
    Walker J; Laycock KA; Pepose JS; Leib DA
    Vaccine; 1998 Jan; 16(1):6-8. PubMed ID: 9607002
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protectivity of herpes simplex virus antigens: studies in mice on the adjuvant effect of PICLC and on the dependence of protection on T cell competence.
    Hilfenhaus J; Christ H; Köhler R; Moser H; Kirchner H; Levy HB
    Med Microbiol Immunol; 1981; 169(4):225-35. PubMed ID: 6268955
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protection from oral herpes simplex virus infection by a nucleic acid-free virus vaccine.
    Kitces EN; Morahan PS; Tew JG; Murray BK
    Infect Immun; 1977 Jun; 16(3):955-60. PubMed ID: 197013
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Murine cytotoxic T lymphocytes specific for herpes simplex virus type 1 recognize the immediate early protein ICP4 but not ICP0.
    Martin S; Zhu XX; Silverstein SJ; Courtney RJ; Yao F; Jenkins FJ; Rouse BT
    J Gen Virol; 1990 Oct; 71 ( Pt 10)():2391-9. PubMed ID: 2172452
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenic properties of formalin herpes antigen prepared from cell cultures.
    Benda R; Dbalý V
    J Hyg Epidemiol Microbiol Immunol; 1973; 17(2):237-49. PubMed ID: 4354219
    [No Abstract]   [Full Text] [Related]  

  • 38. Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D.
    Paoletti E; Lipinskas BR; Samsonoff C; Mercer S; Panicali D
    Proc Natl Acad Sci U S A; 1984 Jan; 81(1):193-7. PubMed ID: 6320164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stimulation of peripheral blood lymphocytes by herpes simplex virus in vitro.
    Scriba M
    Infect Immun; 1974 Sep; 10(3):430-6. PubMed ID: 4372170
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and immune response to rubella subunits vaccines.
    Cappel R; De Cuyper F
    Arch Virol; 1976; 50(3):207-13. PubMed ID: 1259596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.